echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ASCO 2020 Oichtini strength can not be underestimated! 2-year DFS rate of EGFRm non-small cell lung cancer reaches 89%

    ASCO 2020 Oichtini strength can not be underestimated! 2-year DFS rate of EGFRm non-small cell lung cancer reaches 89%

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The 2020 annual meeting of the American Society of Clinical Oncology (ASCO) has been successfully concluded, and this academic feast has been a wonderful event that has won the attention of oncologists around the worldThe most-watched Heavyweight Research Summary (LBA) was officially announced at 5 p.mEST on May 28, with two entries and five LBAs selected for plenary sessionFollow the pace of small editors, turn on the cloud annual meeting mode, take a look at these heavy researchThis issue is shared with an LBA (summary noLBA5) selected for plenary session, which reports a Phase III trial of Ohitinib-assisted treatment of patients with IB-IIIA EGFR mutation-positive (EGFRM) non-small cell lung cancer (NSCLC)Figure 1 ASCO 2020 Selected LBA Study (Summary NoLBA5, Figure: ASCO 2020) Study Background Ohitinib is the third generation of central nervous system activity of EGFR-TKI, which is better than gifitinib and errotini in the late-stage NSCLC of untreated EGFRmApproximately 30% of NSCLC patients are in the early stages (I-IIIA), surgery is the main treatment, and complementary chemotherapy is the standard treatment for NSCLC patients with Phase II-III excision and selected phase IB patients, alADAURA (NCT02511106) is a Phase III, double-blind, randomized study that evaluated the efficacy and safety of Ochtinib compared to placebo (PBO) in NSCLC patients with IB-III EGFRm after the complete removal of tumors and assisted chemotherapyThe trial was not blinded early due to efficacy issues, as recommended by the Independent Data Monitoring Board, and this report is an unplanned interim analysisThe study included 682 eligible patients: 18 years of age and above (20 years of age and above from Japan/Taiwan), WHO physical status score of 0/1, diagnosed with EGFRm (ex19del/L858R) of the primary non-scaly IB/II/IIIA nSCLC, and patients who had a complete excision and full recovery after surgery, allowing chemotherapyPatients were randomly divided into two groups at a 1:1 ratio, receiving oral ochitinib treatment (80 mg, once a day) or PBO treatment for up to 3 years (by staging (IB/II/IIIA), mutation type (ex19del/L858R) and race (Asian/non-Asian) stratificationMain endpoint: Disease-free survival (DFS) in patients with phase II-IIIASecondary endpoint: Total Survival (OS) and securityData Cutoff (DCO): January 17, 2020 The results of the study included 682 patients worldwide and were randomly assigned to the Oxitinib (n-339) treatment group and the PBO treatment group (n-343) Baseline features are arm balance (Ohitini/PBO): IB 31/31%, II/IIIA 69/69%, female 68/72%, ex19del 55/56%, L858R 45/44% In stage II-IIIA patients, the DFS risk ratio (HR) is 0.17 (95% CI 0.12,0.23); The 2-year DFS rate in the Oxitini group was 90% and the PBO group was 44% In the total population, DFS HR is 0.21 (0.16, 0.28); P 0.0001 (196/682); The Ohitini group had 89% DFS for 2 years and 53% in the PBO group On data deadlines, 29 deaths occurred (9 cases in the Ochtinib treatment group and 20 in the PBO treatment group) and the overall OS data were not yet available, and the safety of the known Ochtinib was consistent with that of the known Ochtinib In this global trial, ochedinib has proven to be a clinically beneficial target drug for patients with IB/II/IIIA EGFRm NSCLC after the complete removal of tumors and assisted chemotherapy, providing them with an effective new treatment strategy Ochitinib is the third generation of EGFR-TKI, in 1988, the first researchers proposed EGFR as a potential target for cancer; KI has been reported; in 2013, the second generation of the representative drug afatinib was approved for market; and in 2015, 3 generations of EGFR-TKI "god drug" Ochtinib (9291) were approved for the market, showing high and long-lasting responses to patients with advanced EGFR mutant NSCLC patients with the first and second generation of EGFR-TKI treatment failure At present, clinical treatment found that 1 generation of EGFR-TKI drugs are prone to drug resistance, 2 generations of EGFR-TKI drugs prone to high gastrointestinal and skin toxicity, and there are no 4 generations of small molecular drugs listed (candidates are EAI045, EAI00 1), then as a 3-generation drug ochedinib is undoubtedly at the center of the NSCLC patient treatment stage, the assco conference report of this study once again proved the strength of Ochtinib, hope that EGFR-TKI treatment can go further and further on the path of innovation Related: When will the 4th generation of EGFR-TKI species appear after Ochitini's resistance? Author: Tao Ran Source: Health
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.